Publications by authors named "Peter Vis"

Claim this Profile
P
Pharmacokinetics, Safety, and Dialyzability of Gadoquatrane in Patients With Impaired Renal Function: A Comprehensive Investigation Using Clinical Trial Data, Modeling and Simulation, and In Vitro Data.
Tommaso Fadini, Gabriele Sutter, Stefan Klein, Eva Busemann, Esmée Vendel, Peter Vis

Invest Radiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events.
Ashraf Yassen, Friederike Kanefendt, Jochen Zisowsky, Astrid Broeker, Hardi Mundl, Peter Vis

CPT Pharmacometrics Syst Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of the Neuroprotectant 2-Iminobiotin in Patients With Large-Vessel Occlusion Ischemic Stroke Treated With Endovascular Thrombectomy.
Erik M Vos, Cacha M P C D Peeters-Scholte, Jelis Boiten, Hajo M Hund, Korné Jellema, Peter W Vis

Stroke· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses.
Sebastiaan C Goulooze, Peter W Vis, Elke H J Krekels, Catherijne A J Knibbe

Expert Rev Clin Pharmacol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translation from animal to clinical studies, choosing the optimal moment.
Laurent M A Favié, Cacha M P C D Peeters-Scholte, Anouk Bakker, Huibert Tjabbes, Toine C G Egberts, Peter Vis

Pediatr Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.
Alexander Solms, Alfonso Iorio, Maurice J Ahsman, Peter Vis, Anita Shah

Clin Pharmacokinet· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia.
Laurent M A Favié, Cacha M P C D Peeters-Scholte, Anouk Bakker, Huibert Tjabbes, Toine C G Egberts, Peter Vis

Pediatr Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase IIa Clinical Trial of 2-Iminobiotin for the Treatment of Birth Asphyxia in DR Congo, a Low-Income Country.
Thérèse Biselele, Jephté Bambi, Dieu M Betukumesu, Yoly Ndiyo, Gabriel Tabu, Peter Vis

Paediatr Drugs· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 769 μW Battery-Powered Single-Chip SoC With BLE for Multi-Modal Vital Sign Monitoring Health Patches.
Shuang Song, Mario Konijnenburg, Roland van Wegberg, Jiawei Xu, Hyunsoo Ha, Peter Vis

IEEE Trans Biomed Circuits Syst· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.
Thomas N Kakuda, Anne Brochot, Bruce Green, Steven Nijs, Peter Vis

J Clin Pharmacol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.
Stefanie Hennig, Elin M Svensson, Ronald Niebecker, P Bernard Fourie, Marc H Weiner, Peter Vis

J Antimicrob Chemother· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop.
Klaus Romero, Vikram Sinha, Sandra Allerheiligen, Meindert Danhof, Jose Pinheiro, Peter Vis

J Pharmacokinet Pharmacodyn· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug.
Sarah C McLeay, Peter Vis, Rolf P G van Heeswijk, Bruce Green

Antimicrob Agents Chemother· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.
Thomas Kakuda, Vanitha Sekar, Peter Vis, Bruce Coate, Robert Ryan

AIDS Res Treat· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents.
Stéphane Blanche, Rosa Bologna, Pedro Cahn, Sorin Rugina, Patricia Flynn, Peter Vis

AIDS· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minutes from the round table held in Paris on July 6, 2007: 'Contribution of modelling in the paediatric drug development'.
Christian Laveille, Peter Vis

Fundam Clin Pharmacol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.
Peter Mj Vis, Marc van Baardewijk, Thomas R Einarson

Ann Pharmacother· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis